ACRX:NSD-AcelRx Pharmaceuticals Inc (USD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | NSD

Last Closing Price

USD 0.24

Change

0.00 (0.00)%

Market Cap

USD 0.04B

Volume

0.91M

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict


ACRX Stock Forecast & Price:
Based on the AcelRx Pharmaceuticals Inc stock forecasts from 0 analysts, the average analyst target price for AcelRx Pharmaceuticals Inc is not available over the next 12 months. AcelRx Pharmaceuticals Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of AcelRx Pharmaceuticals Inc is Slightly Bearish, which is based on 4 positive signals and 7 negative signals. At the last closing, AcelRx Pharmaceuticals Inc’s stock price was USD 0.24. AcelRx Pharmaceuticals Inc’s stock price has changed by -14.29% over the past week, -22.58% over the past month and -77.36% over the last year.

About AcelRx Pharmaceuticals Inc (ACRX:NSD)

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-09-24 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
PPD PPD Inc

N/A

USD16.61B 47.04 21.58
VTRS Viatris Inc

N/A

USD10.84B 14.19 6.61
NBIX Neurocrine Biosciences Inc

N/A

USD10.10B 812.54 215.33
MYL Mylan N.V

N/A

USD8.59B 30.73 11.86
APHA Tilray, Inc

N/A

USD6.86B 60.60 454.68
MNTA Momenta Pharmaceuticals, Inc

N/A

USD6.24B N/A N/A
LNTH Lantheus Holdings Inc

N/A

USD4.83B 175.65 46.18
ITCI Intracellular Th

N/A

USD4.18B N/A -12.06
ALKS Alkermes Plc

N/A

USD3.67B N/A -231.07
EVO Evotec SE ADR

N/A

USD3.25B 458.50 69.28

ETFs Containing ACRX

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -57.16% 49% F 26% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -57.16% 49% F 26% F
Trailing 12 Months  
Capital Gain -77.36% 38% F 18% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -77.36% 38% F 18% F
Trailing 5 Years  
Capital Gain -93.85% 29% F 6% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -93.85% 29% F 6% F
Average Annual (5 Year Horizon)  
Capital Gain -23.17% 28% F 12% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -23.17% 28% F 12% F
Risk Return Profile  
Volatility (Standard Deviation) 47.78% 44% F 28% F
Risk Adjusted Return -48.50% 33% F 23% F
Market Capitalization 0.04B 30% F 17% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 0.80 88% B+ 93% A
Price/Book Ratio 1.03 64% D 74% C
Price / Cash Flow Ratio -1.18 55% F 49% F
EV/EBITDA 0.59 31% F 43% F
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital 128.54% 96% A 96% A
Return on Assets -31.29% 18% F 15% F
Debt to Equity Ratio -13.95% 85% B 90% A-
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 2.97 39% F 47% F
Short Percent 7.73% 25% F 20% F
Beta 0.27 87% B+ 90% A-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector